David Stein is a healthcare leader who has spent his career building world-class teams to drive disruptive strategies and innovation in med-tech and diagnostics. His passion for healthcare and improving personal biology began at an early age, starting as an advocate for loved ones. Over time, this passion grew as he sought to manage his own health challenges and excel as a competitive athlete.

David is the CEO of Babson Diagnostics, whose mission is to lower the barriers that prevent people from getting the blood testing they need. Babson developed BetterWay™ blood testing, an affordable, customer-friendly blood test without sacrificing the accuracy and efficiency of laboratory analysis. BetterWay is a simple fingertip collection that uses 1/10th of the volume of conventional venipuncture and is available at Austin pharmacies and clinics. Healthcare organizations across the US can partner with Babson to bring the BetterWay experience to their patients.

Before becoming CEO of Babson Diagnostics in 2020, he was global head of strategy and president of Molecular Diagnostics at Siemens Healthineers, a leading global medical technology company focused on laboratory diagnostics, diagnostic and therapeutic imaging, and molecular medicine. David spent 18 years at Siemens in several leadership roles, including CEO of the point-of-care business, head of strategy for the Diagnostics division, and global vice president of engineering within the Diagnostics division. While at Siemens, he was instrumental in incubating the business that later became Babson Diagnostics.

David serves on the board of directors of Babson Diagnostics and is also the Board Chairman of PixCell Medical, a point-of-care blood diagnostic company in Israel. He earned his Ph.D. in engineering from Johns Hopkins University.